Global CAR T-Cell-Based Drug Market Research Report 2026(Status and Outlook)
Description
Report Overview
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.The CAR T-cell-based drug market is driven by the growing demand for innovative and targeted cancer therapies. Chimeric Antigen Receptor (CAR) T-cell therapy is a revolutionary approach that involves genetically modifying a patient""s T cells to recognize and attack cancer cells. The success of CAR T-cell therapies in treating certain types of blood cancers, such as leukemia and lymphoma, has fueled market growth and encouraged research into expanding the application of CAR T-cell therapy to other solid tumor malignancies. However, the market also faces challenges, including the high cost of CAR T-cell therapy and the complexity of the manufacturing process, which may limit patient access. Additionally, the potential for severe side effects and the need for patient selection and management pose regulatory and clinical challenges. To succeed, companies must focus on advancing research, streamlining the production process, collaborating with healthcare providers to improve patient access and support, and addressing safety and efficacy concerns to establish CAR T-cell-based drugs as a transformative treatment option for cancer patients.
The global CAR T-Cell-Based Drug market size was estimated at USD 5168.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 29.40% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global CAR T-Cell-Based Drug market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global CAR T-Cell-Based Drug market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the CAR T-Cell-Based Drug market.
Global CAR T-Cell-Based Drug Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics
Autolus Therapeutics
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Cellectis
Allogene Therapeutics
Celyad
Market Segmentation (by Type)
CD19-targeted
BCMA-targeted
Market Segmentation (by Application)
Lymphoma
Multiple Myeloma
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the CAR T-Cell-Based Drug Market
Overview of the regional outlook of the CAR T-Cell-Based Drug Market:
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the CAR T-Cell-Based Drug Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of CAR T-Cell-Based Drug, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.The CAR T-cell-based drug market is driven by the growing demand for innovative and targeted cancer therapies. Chimeric Antigen Receptor (CAR) T-cell therapy is a revolutionary approach that involves genetically modifying a patient""s T cells to recognize and attack cancer cells. The success of CAR T-cell therapies in treating certain types of blood cancers, such as leukemia and lymphoma, has fueled market growth and encouraged research into expanding the application of CAR T-cell therapy to other solid tumor malignancies. However, the market also faces challenges, including the high cost of CAR T-cell therapy and the complexity of the manufacturing process, which may limit patient access. Additionally, the potential for severe side effects and the need for patient selection and management pose regulatory and clinical challenges. To succeed, companies must focus on advancing research, streamlining the production process, collaborating with healthcare providers to improve patient access and support, and addressing safety and efficacy concerns to establish CAR T-cell-based drugs as a transformative treatment option for cancer patients.
The global CAR T-Cell-Based Drug market size was estimated at USD 5168.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 29.40% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global CAR T-Cell-Based Drug market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global CAR T-Cell-Based Drug market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the CAR T-Cell-Based Drug market.
Global CAR T-Cell-Based Drug Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics
Autolus Therapeutics
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Cellectis
Allogene Therapeutics
Celyad
Market Segmentation (by Type)
CD19-targeted
BCMA-targeted
Market Segmentation (by Application)
Lymphoma
Multiple Myeloma
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the CAR T-Cell-Based Drug Market
Overview of the regional outlook of the CAR T-Cell-Based Drug Market:
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the CAR T-Cell-Based Drug Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of CAR T-Cell-Based Drug, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
Table of Contents
149 Pages
- 1 Research Methodology and Statistical Scope
- 1.1 Market Definition and Statistical Scope of CAR T-Cell-Based Drug
- 1.2 Key Market Segments
- 1.2.1 CAR T-Cell-Based Drug Segment by Type
- 1.2.2 CAR T-Cell-Based Drug Segment by Application
- 1.3 Methodology & Sources of Information
- 1.3.1 Research Methodology
- 1.3.2 Research Process
- 1.3.3 Market Breakdown and Data Triangulation
- 1.3.4 Base Year
- 1.3.5 Report Assumptions & Caveats
- 2 CAR T-Cell-Based Drug Market Overview
- 2.1 Global Market Overview
- 2.1.1 Global CAR T-Cell-Based Drug Market Size (M USD) Estimates and Forecasts (2020-2035)
- 2.1.2 Global CAR T-Cell-Based Drug Sales Estimates and Forecasts (2020-2035)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region
- 3 CAR T-Cell-Based Drug Market Competitive Landscape
- 3.1 Company Assessment Quadrant
- 3.2 Global CAR T-Cell-Based Drug Product Life Cycle
- 3.3 Global CAR T-Cell-Based Drug Sales by Manufacturers (2020-2025)
- 3.4 Global CAR T-Cell-Based Drug Revenue Market Share by Manufacturers (2020-2025)
- 3.5 CAR T-Cell-Based Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.6 Global CAR T-Cell-Based Drug Average Price by Manufacturers (2020-2025)
- 3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
- 3.8 CAR T-Cell-Based Drug Market Competitive Situation and Trends
- 3.8.1 CAR T-Cell-Based Drug Market Concentration Rate
- 3.8.2 Global 5 and 10 Largest CAR T-Cell-Based Drug Players Market Share by Revenue
- 3.8.3 Mergers & Acquisitions, Expansion
- 4 CAR T-Cell-Based Drug Industry Chain Analysis
- 4.1 CAR T-Cell-Based Drug Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis
- 5 The Development and Dynamics of CAR T-Cell-Based Drug Market
- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Industry News
- 5.4.1 New Product Developments
- 5.4.2 Mergers & Acquisitions
- 5.4.3 Expansions
- 5.4.4 Collaboration/Supply Contracts
- 5.5 PEST Analysis
- 5.5.1 Industry Policies Analysis
- 5.5.2 Economic Environment Analysis
- 5.5.3 Social Environment Analysis
- 5.5.4 Technological Environment Analysis
- 5.6 Global CAR T-Cell-Based Drug Market Porter's Five Forces Analysis
- 5.6.1 Global Trade Frictions
- 5.6.2 U.S. Tariff Policy – April 2025
- 5.6.3 Global Trade Frictions and Their Impacts to CAR T-Cell-Based Drug Market
- 5.7 ESG Ratings of Leading Companies
- 6 CAR T-Cell-Based Drug Market Segmentation by Type
- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global CAR T-Cell-Based Drug Sales Market Share by Type (2020-2025)
- 6.3 Global CAR T-Cell-Based Drug Market Size by Type (2020-2025)
- 6.4 Global CAR T-Cell-Based Drug Price by Type (2020-2025)
- 7 CAR T-Cell-Based Drug Market Segmentation by Application
- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global CAR T-Cell-Based Drug Market Sales by Application (2020-2025)
- 7.3 Global CAR T-Cell-Based Drug Market Size (M USD) by Application (2020-2025)
- 7.4 Global CAR T-Cell-Based Drug Sales Growth Rate by Application (2020-2025)
- 8 CAR T-Cell-Based Drug Market Sales by Region
- 8.1 Global CAR T-Cell-Based Drug Sales by Region
- 8.1.1 Global CAR T-Cell-Based Drug Sales by Region
- 8.1.2 Global CAR T-Cell-Based Drug Sales Market Share by Region
- 8.2 Global CAR T-Cell-Based Drug Market Size by Region
- 8.2.1 Global CAR T-Cell-Based Drug Market Size by Region
- 8.2.2 Global CAR T-Cell-Based Drug Market Size by Region
- 8.3 North America
- 8.3.1 North America CAR T-Cell-Based Drug Sales by Country
- 8.3.2 North America CAR T-Cell-Based Drug Market Size by Country
- 8.3.3 U.S. Market Overview
- 8.3.4 Canada Market Overview
- 8.3.5 Mexico Market Overview
- 8.4 Europe
- 8.4.1 Europe CAR T-Cell-Based Drug Sales by Country
- 8.4.2 Europe CAR T-Cell-Based Drug Market Size by Country
- 8.4.3 Germany Market Overview
- 8.4.4 France Market Overview
- 8.4.5 U.K. Market Overview
- 8.4.6 Italy Market Overview
- 8.4.7 Spain Market Overview
- 8.5 Asia Pacific
- 8.5.1 Asia Pacific CAR T-Cell-Based Drug Sales by Region
- 8.5.2 Asia Pacific CAR T-Cell-Based Drug Market Size by Region
- 8.5.3 China Market Overview
- 8.5.4 Japan Market Overview
- 8.5.5 South Korea Market Overview
- 8.5.6 India Market Overview
- 8.5.7 Southeast Asia Market Overview
- 8.6 South America
- 8.6.1 South America CAR T-Cell-Based Drug Sales by Country
- 8.6.2 South America CAR T-Cell-Based Drug Market Size by Country
- 8.6.3 Brazil Market Overview
- 8.6.4 Argentina Market Overview
- 8.6.5 Columbia Market Overview
- 8.7 Middle East and Africa
- 8.7.1 Middle East and Africa CAR T-Cell-Based Drug Sales by Region
- 8.7.2 Middle East and Africa CAR T-Cell-Based Drug Market Size by Region
- 8.7.3 Saudi Arabia Market Overview
- 8.7.4 UAE Market Overview
- 8.7.5 Egypt Market Overview
- 8.7.6 Nigeria Market Overview
- 8.7.7 South Africa Market Overview
- 9 CAR T-Cell-Based Drug Market Production by Region
- 9.1 Global Production of CAR T-Cell-Based Drug by Region(2020-2025)
- 9.2 Global CAR T-Cell-Based Drug Revenue Market Share by Region (2020-2025)
- 9.3 Global CAR T-Cell-Based Drug Production, Revenue, Price and Gross Margin (2020-2025)
- 9.4 North America CAR T-Cell-Based Drug Production
- 9.4.1 North America CAR T-Cell-Based Drug Production Growth Rate (2020-2025)
- 9.4.2 North America CAR T-Cell-Based Drug Production, Revenue, Price and Gross Margin (2020-2025)
- 9.5 Europe CAR T-Cell-Based Drug Production
- 9.5.1 Europe CAR T-Cell-Based Drug Production Growth Rate (2020-2025)
- 9.5.2 Europe CAR T-Cell-Based Drug Production, Revenue, Price and Gross Margin (2020-2025)
- 9.6 Japan CAR T-Cell-Based Drug Production (2020-2025)
- 9.6.1 Japan CAR T-Cell-Based Drug Production Growth Rate (2020-2025)
- 9.6.2 Japan CAR T-Cell-Based Drug Production, Revenue, Price and Gross Margin (2020-2025)
- 9.7 China CAR T-Cell-Based Drug Production (2020-2025)
- 9.7.1 China CAR T-Cell-Based Drug Production Growth Rate (2020-2025)
- 9.7.2 China CAR T-Cell-Based Drug Production, Revenue, Price and Gross Margin (2020-2025)
- 10 Key Companies Profile
- 10.1 Novartis
- 10.1.1 Novartis Basic Information
- 10.1.2 Novartis CAR T-Cell-Based Drug Product Overview
- 10.1.3 Novartis CAR T-Cell-Based Drug Product Market Performance
- 10.1.4 Novartis Business Overview
- 10.1.5 Novartis SWOT Analysis
- 10.1.6 Novartis Recent Developments
- 10.2 Gilead Sciences
- 10.2.1 Gilead Sciences Basic Information
- 10.2.2 Gilead Sciences CAR T-Cell-Based Drug Product Overview
- 10.2.3 Gilead Sciences CAR T-Cell-Based Drug Product Market Performance
- 10.2.4 Gilead Sciences Business Overview
- 10.2.5 Gilead Sciences SWOT Analysis
- 10.2.6 Gilead Sciences Recent Developments
- 10.3 Bristol-Myers Squibb
- 10.3.1 Bristol-Myers Squibb Basic Information
- 10.3.2 Bristol-Myers Squibb CAR T-Cell-Based Drug Product Overview
- 10.3.3 Bristol-Myers Squibb CAR T-Cell-Based Drug Product Market Performance
- 10.3.4 Bristol-Myers Squibb Business Overview
- 10.3.5 Bristol-Myers Squibb SWOT Analysis
- 10.3.6 Bristol-Myers Squibb Recent Developments
- 10.4 J and J
- 10.4.1 J and J Basic Information
- 10.4.2 J and J CAR T-Cell-Based Drug Product Overview
- 10.4.3 J and J CAR T-Cell-Based Drug Product Market Performance
- 10.4.4 J and J Business Overview
- 10.4.5 J and J Recent Developments
- 10.5 JW Therapeutics
- 10.5.1 JW Therapeutics Basic Information
- 10.5.2 JW Therapeutics CAR T-Cell-Based Drug Product Overview
- 10.5.3 JW Therapeutics CAR T-Cell-Based Drug Product Market Performance
- 10.5.4 JW Therapeutics Business Overview
- 10.5.5 JW Therapeutics Recent Developments
- 10.6 FOSUNKite
- 10.6.1 FOSUNKite Basic Information
- 10.6.2 FOSUNKite CAR T-Cell-Based Drug Product Overview
- 10.6.3 FOSUNKite CAR T-Cell-Based Drug Product Market Performance
- 10.6.4 FOSUNKite Business Overview
- 10.6.5 FOSUNKite Recent Developments
- 10.7 CARsgen Therapeutics
- 10.7.1 CARsgen Therapeutics Basic Information
- 10.7.2 CARsgen Therapeutics CAR T-Cell-Based Drug Product Overview
- 10.7.3 CARsgen Therapeutics CAR T-Cell-Based Drug Product Market Performance
- 10.7.4 CARsgen Therapeutics Business Overview
- 10.7.5 CARsgen Therapeutics Recent Developments
- 10.8 Autolus Therapeutics
- 10.8.1 Autolus Therapeutics Basic Information
- 10.8.2 Autolus Therapeutics CAR T-Cell-Based Drug Product Overview
- 10.8.3 Autolus Therapeutics CAR T-Cell-Based Drug Product Market Performance
- 10.8.4 Autolus Therapeutics Business Overview
- 10.8.5 Autolus Therapeutics Recent Developments
- 10.9 Sorrento Therapeutics
- 10.9.1 Sorrento Therapeutics Basic Information
- 10.9.2 Sorrento Therapeutics CAR T-Cell-Based Drug Product Overview
- 10.9.3 Sorrento Therapeutics CAR T-Cell-Based Drug Product Market Performance
- 10.9.4 Sorrento Therapeutics Business Overview
- 10.9.5 Sorrento Therapeutics Recent Developments
- 10.10 Mustang Bio
- 10.10.1 Mustang Bio Basic Information
- 10.10.2 Mustang Bio CAR T-Cell-Based Drug Product Overview
- 10.10.3 Mustang Bio CAR T-Cell-Based Drug Product Market Performance
- 10.10.4 Mustang Bio Business Overview
- 10.10.5 Mustang Bio Recent Developments
- 10.11 Bluebird Bio
- 10.11.1 Bluebird Bio Basic Information
- 10.11.2 Bluebird Bio CAR T-Cell-Based Drug Product Overview
- 10.11.3 Bluebird Bio CAR T-Cell-Based Drug Product Market Performance
- 10.11.4 Bluebird Bio Business Overview
- 10.11.5 Bluebird Bio Recent Developments
- 10.12 Cellectis
- 10.12.1 Cellectis Basic Information
- 10.12.2 Cellectis CAR T-Cell-Based Drug Product Overview
- 10.12.3 Cellectis CAR T-Cell-Based Drug Product Market Performance
- 10.12.4 Cellectis Business Overview
- 10.12.5 Cellectis Recent Developments
- 10.13 Allogene Therapeutics
- 10.13.1 Allogene Therapeutics Basic Information
- 10.13.2 Allogene Therapeutics CAR T-Cell-Based Drug Product Overview
- 10.13.3 Allogene Therapeutics CAR T-Cell-Based Drug Product Market Performance
- 10.13.4 Allogene Therapeutics Business Overview
- 10.13.5 Allogene Therapeutics Recent Developments
- 10.14 Celyad
- 10.14.1 Celyad Basic Information
- 10.14.2 Celyad CAR T-Cell-Based Drug Product Overview
- 10.14.3 Celyad CAR T-Cell-Based Drug Product Market Performance
- 10.14.4 Celyad Business Overview
- 10.14.5 Celyad Recent Developments
- 11 CAR T-Cell-Based Drug Market Forecast by Region
- 11.1 Global CAR T-Cell-Based Drug Market Size Forecast
- 11.2 Global CAR T-Cell-Based Drug Market Forecast by Region
- 11.2.1 North America Market Size Forecast by Country
- 11.2.2 Europe CAR T-Cell-Based Drug Market Size Forecast by Country
- 11.2.3 Asia Pacific CAR T-Cell-Based Drug Market Size Forecast by Region
- 11.2.4 South America CAR T-Cell-Based Drug Market Size Forecast by Country
- 11.2.5 Middle East and Africa Forecasted Sales of CAR T-Cell-Based Drug by Country
- 12 Forecast Market by Type and by Application (2026-2035)
- 12.1 Global CAR T-Cell-Based Drug Market Forecast by Type (2026-2035)
- 12.1.1 Global Forecasted Sales of CAR T-Cell-Based Drug by Type (2026-2035)
- 12.1.2 Global CAR T-Cell-Based Drug Market Size Forecast by Type (2026-2035)
- 12.1.3 Global Forecasted Price of CAR T-Cell-Based Drug by Type (2026-2035)
- 12.2 Global CAR T-Cell-Based Drug Market Forecast by Application (2026-2035)
- 12.2.1 Global CAR T-Cell-Based Drug Sales (K MT) Forecast by Application
- 12.2.2 Global CAR T-Cell-Based Drug Market Size (M USD) Forecast by Application (2026-2035)
- 13 Conclusion and Key Findings
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
